Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Core Insights - Xilio Therapeutics, Inc. announced a late-breaking poster presentation for vilastobart, a tumor-activated anti-CTLA-4 therapy, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting [1] - The Phase 2 data will focus on the response rate of vilastobart in combination with atezolizumab for patients with microsatellite stable metastatic colorectal cancer and high plasma tumor mutational burden [1] Presentation Details - Abstract Title: Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer [2] - Late-Breaking Abstract Number: 1315 [2] - Presentation Date: November 7, 2025 [2] - Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center [2] - The poster will be available on the Xilio Therapeutics website on the same day [2] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [3] - The company utilizes a proprietary platform to advance a pipeline of novel tumor-activated immuno-oncology molecules designed to enhance therapeutic efficacy within the tumor microenvironment [3]